

55. An isolated polypeptide comprising the epidermal growth factor domain of the leukocyte homing receptor (LHR) amino acid sequence shown in Fig. 1 (SEQ ID NO. 2).

56. An isolated polypeptide comprising a complement binding domain of the leukocyte homing receptor (LHR) amino acid sequence shown in Fig. 1 (SEQ ID NO. 2).--

REMARKS

The drawings are amended in order to correct certain informalities.

The specification is amended to make proper reference to the figure labels appearing in the replacement drawings.

In addition, the specification is amended to recite the history of the present application and to indicate Applicants' claim of priority to parent applications U.S. Ser. No. 08/513,278 filed August 10, 1995, U.S. Ser. No. 08/059,027 filed May 6, 1993 (now abandoned), U.S. Ser. No. 07/786,149 filed October 31, 1991 (now issued as U.S. Pat. No. 5,216,131), and U.S. Ser. No. 07/315,015 filed February 23, 1989 (now issued as U.S. Pat. No. 5,089,833).

Original claims 1-48 are canceled and new claims 49-56 are added. Accordingly, claims 49-56 are pending in the application.

New claim 49 recites an "isolated polypeptide encoded by a DNA able to hybridize under stringent conditions to the complement of a DNA sequence encoding the carbohydrate binding domain, the epidermal growth factor domain or a complement binding domain of the leukocyte homing receptor (LHR) amino acid sequence shown in Fig. 1 (SEQ ID NO. 2)", as supported, at least, on page 5, lines 28-34, page 18, lines 1-7, page 29, lines 11-16, and page 29, lines 29 to page 30, line 2 of the specification, and in original claims 31-33 and 40-42.

New claim 50 recites the polypeptide of claim 49 "wherein the stringent conditions are overnight incubation at 42°C in a solution comprising: 20% formamide, 5XSSC (150 mM NaCl, 15 mM trisodium citrate), 15 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denature, sheared salmon sperm DNA", as supported, at

least, on page 5, lines 28-34, page 18, lines 1-7, page 29, lines 11-16, and page 29, lines 29 to page 30, line 2 of the specification, and in original claims 31-33 and 40-42.

New claim 51 recites the polypeptide of claim 49 “encoded by a DNA able to hybridize under stringent conditions to the complement of a DNA encoding the carbohydrate binding domain of the LHR amino acid sequence shown in Fig. 1 (SEQ ID NO. 2)”, as supported, at least, on page 5, lines 28-34, page 18, lines 1-7, page 29, lines 11-16, and page 29, lines 29 to page 30, line 2 of the specification, and in original claims 31-33 and 40.

New claims 52 and 53 recite the polypeptide of claim 49 “devoid of a functional transmembrane domain” and “devoid of a functional cytoplasmic domain”, respectively, as supported, at least, on page 5, lines 28-34, page 14, lines 1-8, page 17, lines 23-27, page 18, line 28 to page 19, line 26, page 29, lines 11-16, and page 29, lines 29 to page 30, line 2 of the specification, and in original claims 31-33 and 40-42.

New claim 54 recites an “isolated polypeptide comprising the carbohydrate binding domain of the leukocyte homing receptor (LHR) amino acid sequence shown in Fig. 1 (SEQ ID NO. 2)”, as generally supported throughout the specification, and especially in original claim 44.

New claim 55 recites an “isolated polypeptide comprising the epidermal growth factor domain of the leukocyte homing receptor (LHR) amino acid sequence shown in Fig. 1 (SEQ ID NO. 2)”, as generally supported throughout the specification, and especially in original claim 45.

New claim 56 recites an “isolated polypeptide comprising a complement binding domain of the leukocyte homing receptor (LHR) amino acid sequence shown in Fig. 1 (SEQ ID NO. 2)”, as generally supported throughout the specification, and especially in original claim 46.

No new matter is believed to be added hereby.

Respectfully submitted,
GENENTECH, INC.

20 July 1998
1 DNA Way
South San Francisco, CA 94080-4990
Telephone: (650)-225-5530
Fax: (650)-952-9881